Table 4 Odds ratios (95% confidence intervals) of cross-classified quartiles of C-peptide concentration and quartiles of mammographic density parameters on invasive breast cancer risk

From: Plasma C-peptide mammographic features and risk of breast cancer

 

aQuartile of plasma C-peptide concentration

p valueb

Q1

Q2

Q3

Q4

 

Percent MD (%)

    

0.61

Q1, <14.78

1.00 (Ref.)

1.07 (0.60–2.00)

0.94 (0.54–1.67)

1.27 (0.73–2.25)

 

Q2, ≥14.78 to <29.12

1.09 (0.61–2.00)

1.14 (0.53–2.44)

1.44 (0.68–3.02)

1.50 (0.73–3.07)

 

Q3, ≥29.13 to <47.69

2.21 (1.03–3.15)

0.80 (0.39–1.65)

0.72 (0.34–1.47)

1.00 (0.47–2.00)

 

Q4, ≥47.69

1.78 (1.03–3.15)

1.34 (0.65–2.75)

1.42 (0.68–2.93)

1.41 (0.66–2.97)

 

Dense area (cm2)

    

0.96

Q1, <22.42

1.00 (Ref.)

1.24 (0.72–2.12)

1.05 (0.63–1.77)

1.62 (0.96–2.78)

 

Q2, ≥22.42 to <37.56

1.65 (1.00–2.74)

0.80 (0.39–1.58)

0.84 (0.42–1.70)

0.64 (0.32–1.28)

 

Q3, ≥37.56 to <58.57

1.70 (1.02–2.84)

0.93 (0.47–1.89)

1.09 (0.53–2.19)

1.08 (0.54–2.14)

 

Q4, ≥58.57

2.06 (1.24–3.47)

0.88 (0.44–1.75)

0.93 (0.46–1.85)

0.91 (0.45–1.81)

 

Non-dense area (cm2)

    

0.50

Q1, <56.48

1.00 (Ref.)

1.50 (1.00–2.24)

1.16 (0.70–2.24)

1.57 (0.92–2.65)

 

Q2, ≥56.48 to <97.21

0.83 (0.54–1.27)

0.67 (0.37–1.21)

1.11 (0.56–2.21)

0.94 (0.46–1.91)

 

Q3, ≥97.21 to <155.68

0.68 (0.43–1.07)

0.73 (0.39–1.37)

0.76 (0.38–1.53)

1.13 (0.56–2.28)

 

Q4, ≥155.68

0.85 (0.47–1.56)

0.52 (0.25–1.10)

0.59 (0.27–1.30)

0.61 (0.28–1.34)

 

V measure

    

0.07

Q1, <−0.69

1.00 (Ref.)

1.00 (0.49–1.69)

1.45 (0.85–2.54)

1.46 (0.87–2.51)

 

Q2, ≥−0.69 to <0.004

1.28 (0.72–2.31)

1.17 (0.51–2.66)

0.90 (0.42–1.87)

1.16 (0.56–2.39)

 

Q3, ≥0.004 to ≤0.66

1.38 (0.80–2.41)

1.09 (0.50–2.31)

0.71 (0.34–1.50)

0.85 (0.41–1.74)

 

Q4, >0.66

1.37 (0.79–2.42)

1.40 (0.64–3.07)

1.04 (0.50–2.15)

1.19 (0.56–2.50)

 
  1. aAdjusted age, and BMI at blood collection (continuous), at menarche (continuous), age at first birth/parity (nulliparous; 1 or 2 children and <25 years old; 1 or 2 children and 25+ years old; 3+ children and <25 years old; or 3+ children and 25+ years old), physical activity (continuous), alcohol consumption gram/day (continuous), menopausal status (premenopausal; postmenopausal and MHT never users; postmenopausal and former MHT users; postmenopausal and current MHT users), benign breast diseases (yes, no), family history of breast cancer (yes, no), fasting status, diabetes status (yes, no) at blood collection), and waist to hip circumference ratio (continuous) at blood collection and matching factors.
  2. bMultiplicative interaction was tested with a likelihood ratio test through comparing 2 generalized linear models with and without the interaction term.
Back to article page